We are analyzing https://link.springer.com/article/10.1007/s00395-005-0537-4.

Title:
Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo | Basic Research in Cardiology
Description:
Objective Erythropoietin (EPO) is a hormone that is currently used to treat patients with renal failure and anaemia. However, it has also been shown to protect against ischaemia/reperfusion injury; this protection occurring via activation of the ERK 1/2 and PI3K pathways. Since we have previously shown activation of ERK 1/2 and PI3K to be important for protection against reperfusion–induced injury in the myocardium, this study was designed to investigate its effect in the myocardium using both an isolated perfused rat heart and an in vivo rat recovery model of ischaemia–reperfusion. Methods Using an in vitro isolated rat heart model of 35 minutes ischaemia and 2 hours reperfusion, EPO (50 ng/ml) was administered to the rat myocardium 5 minutes prior to reperfusion for 20 minutes. The in vivo open–chest rat model consisted of 40 minutes ischaemia followed by 24 hours reperfusion with EPO (5000 U/kg) being administered at the point of reperfusion. Results In the isolated perfused heart studies 50 ng/ml EPO was found to provide protection with a % I/R of 22.9% ± 6.4 vs 54.5% ± 7.4 for the ischaemic control group. To examine the mechanistic pathways involved in EPO–mediated protection, we co–administered the ERK 1/2 inhibitor, U0126 (10 uM) or the PI3K inhibitors, wortmannin, (100 nM) and LY294002 (15 µM) at reperfusion. U0126, wortmannin and LY294002 all abrogated EPO–mediated protection (% I/R 49.2% ± 5.6, 46.1% ± 5.5 and 49.9% ± 6.1 respectively, p < 0.05). In the in vivo open–chest rat model, the % I/R was significantly attenuated in EPO–treated animals from 53.6 % ± 3.7 in the control to 32.5% +/– 2.9 (p < 0.05). Likewise, wortmannin abrogated EPO–mediated protection (% I/R 50.7 ± 2.3 v EPO 32.5% ± 2.9, p < 0.05). Conclusion We demonstrate that EPO, administered at the point of reperfusion, reduced infarct size in an isolated perfused rat heart, in an ERK and PI3K dependent manner; in addition the mechanism was also confirmed in a whole animal model of ischaemia–reperfusion. These results suggest that EPO may be able to directly protect the myocardium against lethal reperfusion–induced injury and so offer the myocardium an additional clinical advantage over and above its ability to improve the oxygen carrying capacity of the blood.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Insurance
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, google, scholar, erythropoietin, article, reperfusion, injury, heart, myocardium, protects, rat, yellon, protection, epo, erk, effect, vivo, pik, model, access, myocardial, usa, privacy, cookies, content, research, basic, activation, isolated, cerami, brines, ischemiareperfusion, proc, natl, acad, sci, publish, search, vitro, failure, ischaemiareperfusion, minutes, administered, acute, infarction, ischemic, ghezzi, erbayraktar, biol, res,

Topics {✒️}

month download article/chapter article basic research abrogated epo–mediated protection lethal reperfusion–induced injury related subjects acute ischemia–reperfusion injury full article pdf randomized controlled trial privacy choices/manage cookies adult rat cardiomyocytes van veldhuisen dj growth factor signaling acute cardioprotective effect acute myocardial infarction bradykinin limits infarction chronic renal failure london wc1e 6db hypoxia–induced apoptosis cardioprotective effects epo–mediated protection akt–dependent pathway european economic area scope submit manuscript 50 ng/ml mechanistic pathways involved reduced infarct size additional clinical advantage coronary microvascular dysfunction promotes beneficial remodeling broad neuroprotective activity van der meer van gilst wh de montellano pr coronary artery ligation 8–phenyl–4h–1–benzopyran– 4 neonatal hypoxia–ischemia reperfusion–induced injury pi3k dependent manner conditions privacy policy epo–treated animals reperfusion injury revisited oxygen carrying capacity pritchard ka jr ischemia–reperfusion injury reperfused ischemic heart check access instant access accepting optional cookies ischaemic control group erythropoietin receptor expression

Questions {❓}

Yellon DM, Baxter GF (1999) Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo
         description:Erythropoietin (EPO) is a hormone that is currently used to treat patients with renal failure and anaemia. However, it has also been shown to protect against ischaemia/reperfusion injury; this protection occurring via activation of the ERK 1/2 and PI3K pathways. Since we have previously shown activation of ERK 1/2 and PI3K to be important for protection against reperfusion–induced injury in the myocardium, this study was designed to investigate its effect in the myocardium using both an isolated perfused rat heart and an in vivo rat recovery model of ischaemia–reperfusion. Using an in vitro isolated rat heart model of 35 minutes ischaemia and 2 hours reperfusion, EPO (50 ng/ml) was administered to the rat myocardium 5 minutes prior to reperfusion for 20 minutes. The in vivo open–chest rat model consisted of 40 minutes ischaemia followed by 24 hours reperfusion with EPO (5000 U/kg) being administered at the point of reperfusion. In the isolated perfused heart studies 50 ng/ml EPO was found to provide protection with a % I/R of 22.9% ± 6.4 vs 54.5% ± 7.4 for the ischaemic control group. To examine the mechanistic pathways involved in EPO–mediated protection, we co–administered the ERK 1/2 inhibitor, U0126 (10 uM) or the PI3K inhibitors, wortmannin, (100 nM) and LY294002 (15 µM) at reperfusion. U0126, wortmannin and LY294002 all abrogated EPO–mediated protection (% I/R 49.2% ± 5.6, 46.1% ± 5.5 and 49.9% ± 6.1 respectively, p < 0.05). In the in vivo open–chest rat model, the % I/R was significantly attenuated in EPO–treated animals from 53.6 % ± 3.7 in the control to 32.5% +/– 2.9 (p < 0.05). Likewise, wortmannin abrogated EPO–mediated protection (% I/R 50.7 ± 2.3 v EPO 32.5% ± 2.9, p < 0.05). We demonstrate that EPO, administered at the point of reperfusion, reduced infarct size in an isolated perfused rat heart, in an ERK and PI3K dependent manner; in addition the mechanism was also confirmed in a whole animal model of ischaemia–reperfusion. These results suggest that EPO may be able to directly protect the myocardium against lethal reperfusion–induced injury and so offer the myocardium an additional clinical advantage over and above its ability to improve the oxygen carrying capacity of the blood.
         datePublished:2005-06-10T00:00:00Z
         dateModified:2005-06-10T00:00:00Z
         pageStart:397
         pageEnd:403
         sameAs:https://doi.org/10.1007/s00395-005-0537-4
         keywords:
            Erythropoietin
            reperfusion
            ERK 1/2
            PI3K
            Cardiology
         image:
         isPartOf:
            name:Basic Research in Cardiology
            issn:
               1435-1803
               0300-8428
            volumeNumber:100
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Steinkopff-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. J. Bullard
               affiliation:
                     name:University College London Hospital and Medical School
                     address:
                        name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. Govewalla
               affiliation:
                     name:University College London Hospital and Medical School
                     address:
                        name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. M. Yellon
               affiliation:
                     name:University College London Hospital and Medical School
                     address:
                        name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo
      description:Erythropoietin (EPO) is a hormone that is currently used to treat patients with renal failure and anaemia. However, it has also been shown to protect against ischaemia/reperfusion injury; this protection occurring via activation of the ERK 1/2 and PI3K pathways. Since we have previously shown activation of ERK 1/2 and PI3K to be important for protection against reperfusion–induced injury in the myocardium, this study was designed to investigate its effect in the myocardium using both an isolated perfused rat heart and an in vivo rat recovery model of ischaemia–reperfusion. Using an in vitro isolated rat heart model of 35 minutes ischaemia and 2 hours reperfusion, EPO (50 ng/ml) was administered to the rat myocardium 5 minutes prior to reperfusion for 20 minutes. The in vivo open–chest rat model consisted of 40 minutes ischaemia followed by 24 hours reperfusion with EPO (5000 U/kg) being administered at the point of reperfusion. In the isolated perfused heart studies 50 ng/ml EPO was found to provide protection with a % I/R of 22.9% ± 6.4 vs 54.5% ± 7.4 for the ischaemic control group. To examine the mechanistic pathways involved in EPO–mediated protection, we co–administered the ERK 1/2 inhibitor, U0126 (10 uM) or the PI3K inhibitors, wortmannin, (100 nM) and LY294002 (15 µM) at reperfusion. U0126, wortmannin and LY294002 all abrogated EPO–mediated protection (% I/R 49.2% ± 5.6, 46.1% ± 5.5 and 49.9% ± 6.1 respectively, p < 0.05). In the in vivo open–chest rat model, the % I/R was significantly attenuated in EPO–treated animals from 53.6 % ± 3.7 in the control to 32.5% +/– 2.9 (p < 0.05). Likewise, wortmannin abrogated EPO–mediated protection (% I/R 50.7 ± 2.3 v EPO 32.5% ± 2.9, p < 0.05). We demonstrate that EPO, administered at the point of reperfusion, reduced infarct size in an isolated perfused rat heart, in an ERK and PI3K dependent manner; in addition the mechanism was also confirmed in a whole animal model of ischaemia–reperfusion. These results suggest that EPO may be able to directly protect the myocardium against lethal reperfusion–induced injury and so offer the myocardium an additional clinical advantage over and above its ability to improve the oxygen carrying capacity of the blood.
      datePublished:2005-06-10T00:00:00Z
      dateModified:2005-06-10T00:00:00Z
      pageStart:397
      pageEnd:403
      sameAs:https://doi.org/10.1007/s00395-005-0537-4
      keywords:
         Erythropoietin
         reperfusion
         ERK 1/2
         PI3K
         Cardiology
      image:
      isPartOf:
         name:Basic Research in Cardiology
         issn:
            1435-1803
            0300-8428
         volumeNumber:100
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Steinkopff-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. J. Bullard
            affiliation:
                  name:University College London Hospital and Medical School
                  address:
                     name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. Govewalla
            affiliation:
                  name:University College London Hospital and Medical School
                  address:
                     name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. M. Yellon
            affiliation:
                  name:University College London Hospital and Medical School
                  address:
                     name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Basic Research in Cardiology
      issn:
         1435-1803
         0300-8428
      volumeNumber:100
Organization:
      name:Steinkopff-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University College London Hospital and Medical School
      address:
         name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
         type:PostalAddress
      name:University College London Hospital and Medical School
      address:
         name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
         type:PostalAddress
      name:University College London Hospital and Medical School
      address:
         name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. J. Bullard
      affiliation:
            name:University College London Hospital and Medical School
            address:
               name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
               type:PostalAddress
            type:Organization
      name:P. Govewalla
      affiliation:
            name:University College London Hospital and Medical School
            address:
               name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
               type:PostalAddress
            type:Organization
      name:D. M. Yellon
      affiliation:
            name:University College London Hospital and Medical School
            address:
               name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
      name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
      name:The Hatter Institute and centre for Cardiology, University College London Hospital and Medical School, London WC1E 6DB, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(95)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.07s.

LINK . SPRINGER . COM {}